Biohaven BHVN Stock
Biohaven Price Chart
Biohaven BHVN Financial and Trading Overview
| Biohaven stock price | 18.59 USD |
| Previous Close | 24.38 USD |
| Open | 24.11 USD |
| Bid | 22 USD x 800 |
| Ask | 26 USD x 800 |
| Day's Range | 23.78 - 24.54 USD |
| 52 Week Range | 5.54 - 25.84 USD |
| Volume | 671K USD |
| Avg. Volume | 972.4K USD |
| Market Cap | 1.67B USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -9.28 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.6 USD |
BHVN Valuation Measures
| Enterprise Value | 1.31B USD |
| Trailing P/E | N/A |
| Forward P/E | -5.6055045 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 3.5302615 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -2.486 |
Trading Information
Biohaven Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 234.79% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 25.84 USD |
| 52 Week Low | 5.54 USD |
| 50-Day Moving Average | 16.08 USD |
| 200-Day Moving Average | 15.04 USD |
BHVN Share Statistics
| Avg. Volume (3 month) | 972.4K USD |
| Avg. Daily Volume (10-Days) | 1.21M USD |
| Shares Outstanding | 68.23M |
| Float | 51.47M |
| Short Ratio | 6.81 |
| % Held by Insiders | 14.61% |
| % Held by Institutions | 94.77% |
| Shares Short | 6.06M |
| Short % of Float | 10.39% |
| Short % of Shares Outstanding | 8.88% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | N/A |
| Return on Equity (ttm) | -191.81% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -524956000 USD |
| Net Income Avi to Common (ttm) | -543739008 USD |
| Diluted EPS (ttm) | -8.11 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 388.03M USD |
| Total Cash Per Share (mrq) | 5.69 USD |
| Total Debt (mrq) | 29.76M USD |
| Total Debt/Equity (mrq) | 6.3 USD |
| Current Ratio (mrq) | 4.776 |
| Book Value Per Share (mrq) | 6.923 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -316491008 USD |
| Levered Free Cash Flow (ttm) | N/A |
Profile of Biohaven
| Country | United States |
| State | CT |
| City | New Haven |
| Address | 215 Church Street |
| ZIP | 06510 |
| Phone | (203) 404-0410 |
| Website | https://www.biohaven.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; BHV-7010, a Kv7 channel modulator for the treatment of different neurological diseases; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an oral myeloperoxidase inhibitor, which is in Phase 3 clinical trial for the treatment of neurodegenerative diseases. It also offers Taldefgrobep Alfa, an anti-myostatin adnectin, which is in Phase 3 clinical trial for the treatment of spinal muscle atrophy; and BHV-1100 that is in Phase 1a/1b clinical trial for multiple myeloma patients. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.
Q&A For Biohaven Stock
What is a current BHVN stock price?
Biohaven BHVN stock price today per share is 18.59 USD.
How to purchase Biohaven stock?
You can buy BHVN shares on the NYSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Biohaven?
The stock symbol or ticker of Biohaven is BHVN.
Which industry does the Biohaven company belong to?
The Biohaven industry is Biotechnology.
How many shares does Biohaven have in circulation?
The max supply of Biohaven shares is 102.07M.
What is Biohaven Price to Earnings Ratio (PE Ratio)?
Biohaven PE Ratio is now.
What was Biohaven earnings per share over the trailing 12 months (TTM)?
Biohaven EPS is -9.28 USD over the trailing 12 months.
Which sector does the Biohaven company belong to?
The Biohaven sector is Healthcare.
Biohaven BHVN included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| Nasdaq US 700 Small Cap Index NQUS700SC | 1938.96 USD — |
-4.51
|
— — | 1891.68 USD — | 1965.66 USD — | — - | — — |
| NYSE COMPOSITE (DJ) NYA | 17618.61 USD — |
-6.12
|
— — | — — | — — | — - | — — |
- {{ link.label }} {{link}}